Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer
2025-10-01
|
| Col·lecció: | Discover Oncology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1007/s12672-025-03569-x |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|